TRPV6

Across TCGA pan-cancer cohorts, TRPV6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated TRPV6 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher TRPV6 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated TRPV6 expression acts as an unfavorable survival marker, although some lineages such as UCEC and ESCA show a favorable association.

UCEC, PRAD, and BRCA are the cancer types where TRPV6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.949	0.606	.006	34	view →
PRAD	DFS	Median	All	0.157	0.888	<.001	12	view →
BRCA	DFS	Median	II,III,IV	0.358	0.889	<.001	6	view →
COAD	DFS	Median	III,IV	0.170	0.697	.030	3	view →
ESCA	OS	Median	All	0.988	0.497	.046	2	view →
STAD	OS	Median	All	1.000	0.679	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

TRPV6–UCEC (DFS)

Open the UCEC breakdown →